



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ralph A. REISFELD, et al.

Serial No. 10/090,183

Attorney Docket No.: (TSRI-829.0)

Filed: March 2, 2002

Group Art: 1645

For: DNA VACCINE AGAINST
PROLIFERATING ENDOTHELIAL CELLS
AND METHODS OF USE THEREOF

Examiner: Not Yet Assigned

RECEIVED

APR 30 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D. C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56, §1.97 and §1.98, documents that may be material to the examination of this application are listed on the attached PTO-1449 form. Copies of each document are enclosed.

The cited documents disclose numerous specific features. There has been no attempt to enumerate each and every feature disclosed by each document, however. The Examiner is requested to review these documents and to determine the extent of the materiality of the document disclosures, if any, with respect to the present invention.

The discussion of any art and the citation of any document herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that the art or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.

Serial No. 10/090,183
Filed: March 2, 2002

-2-

Also, there is reserved the right to later set forth how the claimed invention is distinguished over the disclosure of any document or other art, including the disclosures of the art and documents recited herein, and that may be cited by the Examiner in rejecting a claim in the instant patent application.

The recitation herein of the art and documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

Respectfully submitted,

By 
Talivaldis Cepuritis (Reg. No. 20,818)


OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180

Serial No. 10/090,183
Filed: March 2, 2002

-3-

CERTIFICATE OF MAILING

I hereby certify that this correspondence and attachments are being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on 23 April 2002


Talivaldis Cepuritis

APR 28 2003

APR 28 2003

PTO/SB/08B (02-03)

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Patent Information Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTC

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **2** of **2****Complete if Known**

Application Number	10/090,183
Filing Date	March 2, 2002
First Named Inventor	Ralph A. REISFELD
Art Unit	1645
Examiner Name	
Attorney Docket Number	TSRI-829.0

RECEIVED
APR 30 2003
TECH CENTER 16012800

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Shin SASAKI, et al., NATURE BIOTECHNOLOGY, Vol. 19, pp. 543-547 (June 2001).	
		Nicholas P. RESTIFO, NATURE BIOTECHNOLOGY, Vol. 19, pp. 527-528 (June 2001).	
		Wolfgang W. LEITNER, et al., CANCER RESEARCH, Vol. 60, pp. 51-55 (January 1, 2000).	
		N. P. RESTIFO et al. GENE THERAPY Vol 7 pp 89-92 (2000)	
		Bruce A. KEYT, et al., THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 10, pp. 5638-5646 (1996).	
		Yu-Quan WEI, et al., NATURE MEDICINE, Vol. 6, No. 10, pp. 1160-1166 (October 2000)	
		William MATTHEWS, et al., PROC. NAT'L. ACAD. SCI., USA, Vol. 88, pp 9026-9030 (October 1991)	
		Timothy P. QUINN, et al., PROC. NAT'L. ACAD. SCI., USA, Vol. 90, pp 7533-7537 (Aug. 1993).	
		Rong XIANG, et al., CLINICAL CANCER RESEARCH, Vol. 7 pp. 856s-864s (March 2001) (Suppl.)	
		Andreas G. NIETHAMMER et al. NATURE MEDICINE Vol 8 (12) pp 1369-1375 (December, 2002)	

Examiner Signature	Date	Considered
--------------------	------	------------

* EXAMINER Initial: Reference considered, whether or not citation is in compliance with MPEP 509. Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to be used by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

If you need assistance in completing the form, call 1-800/PTO 9199 (1-800-786-9199) and select option 2